A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer

Authors

Cathy Eng, MD Anderson Cancer Center
Marwan Fakih, City of Hope Comprehensive Cancer Center
Manik Amin, Washington University School of Medicine in St. Louis
Van Morris, MD Anderson Cancer Center
Howard S. Hochster, Rutgers Cancer Institute
Patrick M. Boland, Roswell Park Cancer Institute
Hope Uronis, Duke Cancer Institute

Journal

Oncotarget

Publication Date

4-14-2020

Volume

11

Issue

15

First Page

1334

Last Page

1343

Document Type

Open Access Publication

DOI

10.18632/oncotarget.27536

Rights and Permissions

Eng C, Fakih M, Amin M, et al. A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget. 2020;11(15):1334-1343. Published 2020 Apr 14. doi:10.18632/oncotarget.27536. Copyright: Eng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Eng, Cathy; Fakih, Marwan; Amin, Manik; Morris, Van; Hochster, Howard S.; Boland, Patrick M.; and Uronis, Hope, "A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer." Oncotarget. 11, 15. 1334 - 1343. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9355